查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591978

肺癌免疫查核點抑制劑市場：按產品類型、最終用戶分類 - 全球預測 2025-2030

Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺癌免疫查核點抑制劑市值為10.1億美元，預計2024年將達11.5億美元，複合年成長率為14.55%，2030年將達26億美元，預計將達到2000萬美元。

肺癌免疫查核點抑制劑（ICIs）是癌症藥物市場的重要組成部分，是透過靶向PD-1、PD-L1和CTLA-4等蛋白質來增強針對癌細胞的免疫反應的藥物。與傳統化療相比，ICIs 的需求增加了顯著提高存活率並提供個人化治療化療的能力，以對抗非小細胞肺癌 (NSCLC)，約佔肺癌患者的 85%。這些抑制劑通常與其他治療方法（例如化療）合併使用，用於第一線或一線治療應用。主要最終用戶包括世界各地的醫院、專科診所和癌症研究中心。市場成長的推動因素包括肺癌盛行率的增加、診斷技術的進步、治療方案中擴大採用 ICI，以及導致新產品推出的持續研究和開發。在醫療基礎設施改善和醫療成本上升的推動下，新興市場為市場擴張提供了廣泛的機會。然而，治療成本高、患者反應變化以及免疫相關副作用等限制對更廣泛的市場滲透提出了挑戰。此外，核准流程方面的監管障礙也阻礙了成長。為了利用這些機會，鼓勵公司投資於生物標記開發的研究，以對患者進行分層並改善治療結果。與生物技術公司和醫療機構的合作還可以促進創新並擴大應用範圍。良好的創新領域包括開發下一代抑制劑和減輕抗藥性的聯合治療。該市場競爭激烈且未來性，投資管道開拓和策略聯盟對於獲得競爭優勢至關重要。相關人員必須繼續監控監管趨勢和新興研究，以確保符合市場需求並有效預測未來的變化。

主要市場統計
基準年[2023] 10.1億美元
預測年份 [2024] 11.5億美元
預測年份 [2030] 26.2億美元
複合年成長率（%） 14.55%

市場動態：快速發展的肺癌免疫查核點抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變肺癌免疫查核點抑制劑的市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 肺癌盛行率高，需要免疫查核點抑制劑
    • 政府對癌症研究和治療的投資
    • 監管產品核可增加
  • 市場限制因素
    • 免疫查核點抑制劑治療價格和報銷限制
  • 市場機會
    • 開發用於免疫查核點抑制劑治療的有前景的預測生物標記
    • 免疫查核點抑制劑與其他抗癌藥物的組合
  • 市場挑戰
    • 查核點抑制劑缺乏研究標準化
    • 免疫查核點抑制劑可能的副作用

波特五力：開拓肺癌免疫查核點抑制劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對肺癌免疫查核點抑制劑市場的影響

外部宏觀環境因素在塑造肺癌免疫查核點抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肺癌免疫查核點抑制劑市場的競爭格局

肺癌免疫查核點抑制劑市場的詳細市場佔有率分析提供了對供應商業績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣供應商在肺癌市場免疫查核點抑制劑方面的績效評估

FPNV 定位矩陣是評估肺癌免疫查核點抑制劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了肺癌免疫查核點抑制劑市場的成功之路

對肺癌免疫查核點抑制劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肺癌盛行率高，需要免疫查核點抑制劑
      • 政府對癌症研究和治療的投資
      • 監管產品核可增加
    • 抑制因素
      • 免疫查核點抑制劑治療的經濟負擔和報銷有限
    • 機會
      • 開發用於免疫查核點抑制劑治療的有前景的預測生物標記
      • 免疫查核點抑制劑與其他抗癌藥物的組合
    • 任務
      • 查核點抑制劑缺乏研究標準化
      • 免疫查核點抑制劑可能的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肺癌免疫查核點抑制劑市場：依產品

  • Atezolizumab
  • Durvalumab
  • 納武單抗
  • Pembrolizumab

第7章肺癌免疫查核點抑制劑市場：按類型

  • CTLA-4抑制劑
  • PD-1抑制劑
  • PD-L1抑制劑

第8章肺癌免疫查核點抑制劑市場：依最終用戶分類

  • 學術研究所
  • 醫院
  • 製藥和生物技術公司

第9章 美洲肺癌免疫查核點抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區肺癌免疫查核點抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲肺癌免疫查核點抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeyondSpring Pharmaceuticals Inc.
  • BioLineRx Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • IQVIA Inc.
  • Jazz Pharmaceuticals PLC
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Mirati Therapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
Product Code: MRR-E40E525C3802

The Immune Checkpoint Inhibitors for Lung Cancer Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.15 billion in 2024, and is projected to grow at a CAGR of 14.55%, to USD 2.62 billion by 2030.

Immune Checkpoint Inhibitors (ICIs) for lung cancer represent a vital segment of the oncology therapeutics market, focusing on agents that target proteins such as PD-1, PD-L1, and CTLA-4 to boost the immune response against cancer cells. The necessity of ICIs arises from their ability to significantly improve survival rates over traditional chemotherapy, offering a personalized treatment approach in battling non-small-cell lung cancer (NSCLC), which constitutes about 85% of lung cancer cases. These inhibitors find applications in first and subsequent lines of treatment, often combined with other therapies like chemotherapy. The key end-users include hospitals, specialty clinics, and cancer research centers globally. Market growth is propelled by factors such as increased prevalence of lung cancer, advancements in diagnostic technologies, growing adoption of ICIs in treatment protocols, and continuous R&D leading to new product launches. Emerging markets, driven by improving healthcare infrastructure and increasing healthcare expenditure, offer promising opportunities for expansion. However, limitations such as high treatment costs, diversity in patient response, and immune-related adverse effects present challenges to broader market penetration. Additionally, regulatory hurdles concerning approval processes also impede growth. To capitalize on opportunities, companies are encouraged to invest in research focusing on biomarker development to enhance patient stratification and improve therapeutic outcomes. Collaborations with biotechnology firms and healthcare institutions can also spur innovation and broaden the application spectrum. Areas ripe for innovation include developing next-generation inhibitors and combination therapies that mitigate resistance. The market's nature is competitive yet promising, with considerable investment in pipeline development and strategic partnerships crucial for gaining a competitive edge. Stakeholders should continue monitoring regulatory trends and emerging research to ensure alignment with market demands and to anticipate future changes effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.15 billion
Forecast Year [2030] USD 2.62 billion
CAGR (%) 14.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immune Checkpoint Inhibitors for Lung Cancer Market

The Immune Checkpoint Inhibitors for Lung Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of lung cancer necessitating immune checkpoint inhibitors
    • Government investment in cancer research and treatment
    • Increasing product approval by regulatory agencies
  • Market Restraints
    • Limited affordability and reimbursement for immune checkpoint inhibitor therapies
  • Market Opportunities
    • Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
    • Combination of immune checkpoint inhibitors with other cancer therapies
  • Market Challenges
    • Lack of research standardization of checkpoint inhibitors
    • Possible side-effects of immune checkpoint inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Immune Checkpoint Inhibitors for Lung Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immune Checkpoint Inhibitors for Lung Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immune Checkpoint Inhibitors for Lung Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immune Checkpoint Inhibitors for Lung Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immune Checkpoint Inhibitors for Lung Cancer Market

A detailed market share analysis in the Immune Checkpoint Inhibitors for Lung Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immune Checkpoint Inhibitors for Lung Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immune Checkpoint Inhibitors for Lung Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immune Checkpoint Inhibitors for Lung Cancer Market

A strategic analysis of the Immune Checkpoint Inhibitors for Lung Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors for Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bayer AG, BeyondSpring Pharmaceuticals Inc., BioLineRx Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, IQVIA Inc., Jazz Pharmaceuticals PLC, Laboratory Corporation of America Holdings, Merck KGaA, Mirati Therapeutics Inc., and Ono Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors for Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab.
  • Based on Type, market is studied across CTLA-4 Inhibitors, PD-1 Inhibitors, and PD-L1 Inhibitors.
  • Based on End-Users, market is studied across Academic & Research Institutes, Hospitals, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
      • 5.1.1.2. Government investment in cancer research and treatment
      • 5.1.1.3. Increasing product approval by regulatory agencies
    • 5.1.2. Restraints
      • 5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
      • 5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of research standardization of checkpoint inhibitors
      • 5.1.4.2. Possible side-effects of immune checkpoint inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products

  • 6.1. Introduction
  • 6.2. Atezolizumab
  • 6.3. Durvalumab
  • 6.4. Nivolumab
  • 6.5. Pembrolizumab

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type

  • 7.1. Introduction
  • 7.2. CTLA-4 Inhibitors
  • 7.3. PD-1 Inhibitors
  • 7.4. PD-L1 Inhibitors

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals
  • 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. BeyondSpring Pharmaceuticals Inc.
  • 5. BioLineRx Ltd.
  • 6. Bristol-Myers Squibb Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Genentech, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. IQVIA Inc.
  • 11. Jazz Pharmaceuticals PLC
  • 12. Laboratory Corporation of America Holdings
  • 13. Merck KGaA
  • 14. Mirati Therapeutics Inc.
  • 15. Ono Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023